First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

(2016) Ahmad Awada et al.   JAMA Oncology

Activity of T-DM1 in Her2-positive breast cancer brain metastases

(2015) Rupert Bartsch et al.   CLINICAL & EXPERIMENTAL METASTASIS

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2015) Xavier Pivot et al.   JOURNAL OF CLINICAL ONCOLOGY

New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies

(2015) David Westover et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

(2015) Bi-Yun Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

(2015) Sara A Hurvitz et al.   LANCET ONCOLOGY

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

(2014) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Sharon H. Giordano et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Naren Ramakrishna et al.   JOURNAL OF CLINICAL ONCOLOGY

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

(2014) Zhaomei Mu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Molecular signatures of lymph node status by intrinsic subtype: gene expression analysis of primary breast tumors from patients with and without metastatic lymph nodes

(2014) Craig D Shriver et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Early-onset colorectal cancer patients without family history are “at very low risk” for lynch syndrome

(2014) Vittoria Stigliano et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer

(2014) Jessica M Baron et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry

(2013) R. Bartsch et al.   ANNALS OF ONCOLOGY

Treatment of HER2-positive breast cancer

(2013) Maria Cristina Figueroa-Magalhães et al.   BREAST

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

(2013) Sara A. Hurvitz et al.   BREAST CANCER RESEARCH AND TREATMENT

Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer

(2013) I. Krop et al.   CLINICAL CANCER RESEARCH

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

(2013) Baris Boyraz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer

(2013) Parvin F Peddi et al.   Future Oncology

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2013) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer brain metastases responding to primary systemic therapy with T-DM1

(2013) Rupert Bartsch et al.   JOURNAL OF NEURO-ONCOLOGY

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

(2013) Filippo Montemurro et al.   Molecular Oncology

New Target Therapies for Brain Metastases from Breast Cancer

(2012) G. Metro et al.   CURRENT CANCER DRUG TARGETS

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

(2012) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

(2011) J. Huober et al.   BREAST

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

Clinical implementation of the intrinsic subtypes of breast cancer

(2010) Charles M Perou et al.   LANCET ONCOLOGY

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

(2009) W. Scheuer et al.   CANCER RESEARCH

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

HER-2-positive metastatic breast cancer: trastuzumab and beyond

(2008) Giulio Metro et al.   EXPERT OPINION ON PHARMACOTHERAPY

Targeting Her-2/neu in Breast Cancer: As Easy as This!

(2008) Hamdy Azim et al.   ONCOLOGY